Vantage Investment Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Vantage Investment Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-80	Closed	–	–	895
2016 Q2	$0	Hold	80	–	–	﹤0.01%	943
2016 Q1	$0	Hold	80	–	–	﹤0.01%	890
2015 Q4	$1K	Hold	80	–	–	﹤0.01%	763
2015 Q3	$1K	Hold	80	–	–	﹤0.01%	773
2015 Q2	$2K	Sell	80 -80	-50%	-$1.54K	﹤0.01%	701
2015 Q1	$3K	Buy	160 +80	+100%	+$1.8K	﹤0.01%	752
2014 Q4	$2K	Hold	80	–	–	﹤0.01%	725
2014 Q3	$2K	Hold	80	–	–	﹤0.01%	680
2014 Q2	$2K	Hold	80	–	–	﹤0.01%	671
2014 Q1	$3K	Hold	80	–	–	﹤0.01%	597
2013 Q4	$2K	Buy	+80	New	+$1.46K	﹤0.01%	602

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Vantage Investment Advisors's CTIC Position: Q3 2016 in Review

Vantage Investment Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2016, closing a stake of 80 shares.

Vantage Investment Advisors first reported a position in CTIC in Q4 2013 and held it in 11 quarters. The position peaked at $3K in Q1 2015. 61 funds tracked by Wall St. Rank hold CTIC as of Q3 2016.

Vantage Investment Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2016 after selling out during the quarter.
Vantage Investment Advisors sold 80 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2016.
Vantage Investment Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2013 and held it in 11 quarters.
Vantage Investment Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $3K in Q1 2015.
61 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2016.

Based on Vantage Investment Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.